Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC(50)/MIC(90), 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptoco...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfaller, Michael A., Huband, Michael D., Shortridge, Dee, Flamm, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Epidemiology and Surveillance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913935/
https://www.ncbi.nlm.nih.gov/pubmed/29378719
http://dx.doi.org/10.1128/AAC.02327-17
Descripción
Sumario:Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against Staphylococcus aureus (MIC(50)/MIC(90), 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC(50)/MIC(90), 0.06/0.12 mg/liter), including Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae, including Escherichia coli (MIC(50)/MIC(90), 0.5/2 mg/liter); Haemophilus influenzae (MIC(50)/MIC(90), 1/1 mg/liter); and Moraxella catarrhalis (MIC(50)/MIC(90), 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.

Ejemplares similares